8-K: PMGC Holdings Subsidiary, Northstrive Biosciences, Presents Novel Obesity Drug Candidates at UCLA Symposium

Northstrive Biosciences, a subsidiary of PMGC Holdings Inc., presented its obesity drug candidates, EL-22 and EL-32, at the UCLA Obesity Symposium.

Summary

• PMGC Holdings Inc.'s subsidiary, Northstrive Biosciences, attended the UCLA Obesity Symposium and presented its novel obesity drug candidates, EL-22 and EL-32.
• The presentation highlighted the potential of these drugs to address the issue of muscle loss associated with GLP-1 treatments.
• EL-22 is a myostatin-engineered probiotic with completed Phase 1 clinical trials showing good safety and tolerability.
• EL-32 is a dual myostatin/Activin-A engineered probiotic currently in preclinical development.
• Northstrive Biosciences aims to be an early mover in the GLP-1 combination space with its oral myostatin formulations.

Sentiment

Score: 7

Explanation: The document presents promising preclinical and Phase 1 data for Northstrive Biosciences' obesity drug candidates, suggesting potential for future success. However, it also includes forward-looking statements and disclaimers, indicating inherent risks and uncertainties.

Positives

• EL-22 has completed Phase 1 clinical trials and demonstrated good safety and tolerability.
• EL-22 has shown promising preclinical results in DMD mice models, inhibiting weight loss and improving muscle strength.
• EL-32 has shown statistically significant antibody production in preclinical studies.
• Northstrive Biosciences is targeting an unmet need in obesity treatment by preserving muscle mass during weight loss.
• The company aims to be an early mover in the GLP-1 combination space with its oral myostatin formulations.

Risks

• Forward-looking statements are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict.
• Actual results may differ materially from those contemplated by the forward-looking statements due to various factors, including market and regulatory conditions.

Future Outlook

Northstrive Biosciences plans to achieve several milestones, including a pre-IND meeting in 2025, an EL-32 IND filing in 2026, and initiation of an EL-22 + GLP-1 Phase 2 Proof of Concept study in 2027, assuming FDA clearance.

Industry Context

The presentation highlights the growing interest in combination therapies for obesity, particularly those that address muscle loss associated with GLP-1 treatments, as evidenced by Eli Lilly's acquisition of Versanis and Regeneron's preclinical studies.

Comparison to Industry Standards

• Eli Lilly's $1.9 billion acquisition of Versanis demonstrates the industry's validation of the myostatin pathway as a target for muscle preservation.
• Regeneron's preclinical myostatin+GLP-1 combo studies further support the potential of combination therapies in addressing obesity.
• Northstrive Biosciences aims to be an early mover in the GLP-1 combination space with its oral myostatin formulations, differentiating itself from injectable or other routes of administration.

Stakeholder Impact

• Shareholders may benefit from the potential success of Northstrive Biosciences' drug candidates.
• Employees may have opportunities for growth and development within the company.
• Customers (patients) may have access to new and effective obesity treatments.
• Suppliers and collaborators may benefit from partnerships with Northstrive Biosciences.
• Creditors may have increased confidence in the company's financial stability.

Next Steps

• Pre-IND meeting in 2025.
• Announce cGMP partner in 2025.
• Recruit team members in 2025.
• EL-32 IND filing in 2026.
• Announce strategic collaboration and PoC Data Readout in 2026.
• Run Preclinical GPL-1 Combination Studies for EL-22 and EL-32 in 2026.
• EL-22 IND filing in 2026.
• Expand Northstrive Pipeline in 2026.
• Initiate EL-22 + GLP-1 Phase 2 PoC in 2027 (assumes FDA clears IND).

Key Dates